echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > ​Tecoro TDM-105795 Initiates Phase Ib Human Clinical Trial of Androgenetic Alopecia

    ​Tecoro TDM-105795 Initiates Phase Ib Human Clinical Trial of Androgenetic Alopecia

    • Last Update: 2022-05-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 28, 2022, Tecoro Bio announced that its topical TDM-105795 tincture for patients with androgenetic alopecia (AGA) completed the first clinical phase 1b (MAD) trial in the United States on February 23 last week.


    The Phase 1b clinical trial is a 28-day multiple dose escalation study, which is a "randomized, double-blind, vehicle-controlled, parallel group, multiple dose escalation study to evaluate the efficacy of TDM-105795 in patients with androgenic Safety, tolerability and pharmacokinetics in healthy male subjects with alopecia


    About TDM-105795

    About TDM-105795

    TDM-105795 is a small molecule drug candidate that is a topical drug that promotes hair growth


    About Androgenetic Alopecia (AGA)

    About Androgenetic Alopecia (AGA)

    Androgenetic alopecia (AGA), also known as male or female pattern baldness, is the most common type of hair loss affecting both men and women, with a higher incidence in men


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.